Curcumin: A new candidate for melanoma therapy?

International Journal of Cancer

Volumn 139, Issue 8, 2016, Pages 1683-1695

  Mirzaei, Hamed ^a   Naseri, Gholamreza ^b   Rezaee, Ramin ^c   Mohammadi, Mohsen ^d   Banikazemi, Zarrin ^a   Mirzaei, Hamid Reza ^e   Salehi, Hossein ^f   Peyvandi, Mostafa ^a,g   Pawelek, John M ^h   Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NORTH KHORASAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h YALE CANCER CENTER   (United States)

Author keywords

cancer; curcumin; melanoma; therapy

Indexed keywords

CURCUMIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; OSTEOPONTIN; PHOSPHOLIPID; POLYPHENOL; PROTEIN BCL 2; PROTEIN P21;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER REGRESSION; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MELANOMA; METASTASIS; MICELLE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 84978410859     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30224     Document Type: Review

References (170)

1. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway. Biochem Biophys Res Commun 2015; 286–91.
2. Thangapazham RL, Sharad S, Maheshwari RK. Skin regenerative potentials of curcumin. Biofactors 2013; 39:141–9.
3. Panahi Y, Saadat A, Beiraghdar F, et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28:1461–7.
4. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applicationsCurr. Med Chem 2010; 17:190–7.
5. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Nat Prod Res 2015; 29:491–2.
6. Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 2015; 21:332–8.
7. Sahebkar A, Mohammadi A, Atabati A, et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013; 27:1883–8.
8. Panahi Y, Sahebkar A, Amiri M, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 2012; 108:1272–9.
9. Panahi Y, Ghanei M, Hajhashemi A, et al. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J Diet Suppl 2016; 13:93–105.
10. Panahi Y, Alishiri GH, Parvin S, et al. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl 2016; 13:209–20.
11. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28:633–42.
12. Panahi Y, Sahebkar A, Parvin S, et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49:580–8.
13. Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr 2015; 34:1101–8.
14. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014; 11:123
15. Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol 2014; 114:437–8.
16. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 2014; 22:851–7.
17. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013; 27:374–9.
18. Panahi Y, Rahimnia AR, Sharafi M, et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28:1625–31.
19. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? BioFactors 2013; 39:197–208.
20. Swamy AV, Gulliaya S, Thippeswamy A, et al. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 2012; 44:73–7
21. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010; 94:e75–6.
22. Panahi Y, Badeli R, Karami GR, et al. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 2015; 29:17–21.
23. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, et al. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012; 35:2121–7.
24. Mythri RB, Bharath MM. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr Pharm Des 2012; 18:91–9.
25. Sahebkar A. Autophagic activation: a key piece of the puzzle for the curcumin-associated cognitive enhancement? J Psychophar 2016; 30:93–4.
26. Jiang Z, Guo M, Shi C, et al. Protection against cognitive impairment and modification of epileptogenesis with curcumin in a post-status epilepticus model of temporal lobe epilepsy. Neuroscience 2015; 310:362–71.
27. Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychophar 2015; 29:642–51.
28. Shakeri A, Sahebkar A. Optimized curcumin formulations for the treatment of Alzheimer's disease: a patent evaluation. J Neurosci Res 2016; 94:111–3.
29. Hasan ST, Zingg JM, Kwan P, et al. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014; 232:40–51.
30. Lu Y, Miao L, Wang Y, et al. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther 2016; 24:364–74.
31. Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med 2006; 355:51–65.
32. Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 2015; 6:42008–18. Dec 8;:-.
33. Uzarska M, Czajkowski R, Schwartz RA, et al. Chemoprevention of skin melanoma: facts and myths. Melanoma Res 2013; 23:426–33.
34. Akabane H, Sullivan RJ. The future of molecular analysis in melanoma: diagnostics to direct molecularly targeted therapy. Am J Clin Dermatol 2016; 17:1–10.
35. Faiao-Flores F, Quincoces Suarez JA, Fruet AC, et al. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. PloS One 2015; 10:e0118702
36. Loch-Neckel G, Santos-Bubniak L, Mazzarino L, et al. Orally administered chitosan-coated polycaprolactone nanoparticles containing curcumin attenuate metastatic melanoma in the lungs. J Pharm Sci 2015; 104:3524–34.
37. Nguyen TA, Friedman AJ. Curcumin: a novel treatment for skin-related disorders. J Drugs Dermatol 2013; 12:1131–7.
38. Dahmke IN, Backes C, Rudzitis-Auth J, et al. Curcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly altered. PloS One 2013; 8:e81122
39. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF-kappaB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS One 2013; 8:e71130
40. Li XJ, Li YZ, Jin CT, et al. Curcumin induces apoptosis by PTEN/PI3K/AKT pathway in EC109 cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2015; 31:174–7.
41. Bhavani Shankar T, Shantha N, Ramesh H, et al. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs and monkeys. Indian J Exp Biol 1980; 18:73–5.
42. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6:10
43. Zhang J, Tang Q, Xu X, et al. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. Int J Pharm 2013; 448:168–74.
44. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41:40–59.
45. Kurien BT, Singh A, Matsumoto H, et al. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007; 5:567–76.
46. Mancuso C, Siciliano R, Barone E. Curcumin and Alzheimer disease: this marriage is not to be performed. J Biol Chem 2011; 286:le3
47. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4:807–18.
48. Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules 2015; 20:185–205.
49. Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 2009; 10:97–108.
50. Sultana R. Ferulic acid ethyl ester as a potential therapy in neurodegenerative disorders. Biochim Biophys Acta 2012; 1822:748–52.
51. Kurien BT, Scofield RH. Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification—an in vitro study. J Ethnopharmacol 2007; 110:368–73.
52. Zhao L, Yang C, Dou J, et al. Development of RGD-functionalized PEG-PLA micelles for delivery of curcumin. J Biomed Nanotechnol 2015; 11:436–46.
53. Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAPalphac vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-alpha in melanoma. Oncotarget 2015; 6:25932–42.
54. Siwak DR, Shishodia S, Aggarwal BB, et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005; 104:879–90.
55. Lu C, Song E, Hu DN, et al. Curcumin induces cell death in human uveal melanoma cells through mitochondrial pathway. Curr Eye Res 2010; 35:352–60.
56. Bush JA, Cheung KJ, Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271:305–14.
57. Zhang YP, Li YQ, Lv YT, et al. Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. Genet Mol Res 2015; 14:1056–67.
58. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003; 278:14487–97.
59. McCarthy MM, Pick E, Kluger Y, et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008; 19:590–4.
60. Miyagawa T, Saito H, Minamiya Y, et al. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature. Int J Clin Oncol 2014; 19:722–30.
61. Fang BM, Jiang JH, Zhang XW, et al. Curcumin enhances bortezomib treatment of myeloma by inhibiting heat shock protein 90 expression. Trop J Pharm Res 2015; 14:227–33.
62. Calabrese V, Guagliano E, Sapienza M, et al. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem Res 2007; 32:757–73.
63. Mancuso C, Scapagini G, Curro D, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007; 12:1107–23.
64. Mancuso C, Santangelo R, Calabrese V. The heme oxygenase/biliverdin reductase system: a potential drug target in Alzheimer s disease. J Biol Reg Homeos Ag 2012; 27:75–87.
65. Arena V, Pennacchia I, Guerriero G, et al. The heme oxygenase/biliverdin reductase system in skin cancers. J Biol Reg Homeos Ag 2014; 29:259–64.
66. Calabrese V, Bates TE, Mancuso C, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res 2008; 52:1062–73.
67. Goodpasture C, Arrighi F. Effects of food seasonings on the cell cycle and chromosome morphology of mammalian cells in vitro with special reference to turmeric. Food Cosmet Toxicol 1976; 14:9–14.
68. Giri A, Das SK, Talukder G, et al. Sister chromatid exchange and chromosome aberrations induced by curcumin and tartrazine on mammalian cells in vivo. Cytobios 1989; 62:111–7.
69. Burgos-Morón E. Calderón-Montaño JM, Salvador J, et al. The dark side of curcumin. Int J Cancer 2010; 126:1771–5.
70. Kurien BT, Dillon SP, Dorri Y, et al. Curcumin does not bind or intercalate into DNA and a note on the gray side of curcumin. Int J Cancer 2011; 128:242–5.
71. Mancuso C, Barone E. Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci 2009; 30:333–4.
72. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway. Biochem Biophys Res Commun 2015; 464:286–91.
73. Wolnicka-Glubisz A, Nogal K, Zadlo A, et al. Curcumin does not switch melanin synthesis towards pheomelanin in B16F10 cells. Arch Dermatol Res 2015; 307:89–98.
74. Jiang AJ, Jiang G, Li LT, et al. Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells. Mol Biol Rep 2015; 42:267–75.
75. Oelkrug C, Lange CM, Wenzel E, et al. Analysis of the tumoricidal and anti-cachectic potential of curcumin. Anticancer Res 2014; 34:4781–8.
76. Chen J, Li L, Su J, et al. Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin. PloS One 2014; 9:e101277
77. Qiu Y, Yu T, Wang W, et al. Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. Biochem. Biophys Res Commun 2014; 448:15–21.
78. Buss S, Dobra J, Goerg K, et al. Visible light is a better co-inducer of apoptosis for curcumin-treated human melanoma cells than UVA. PloS One 2013; 8:e79748
79. Yu T, Ji J, Guo YL. MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. Biochem Biophys Res Commun 2013; 441:53–8.
80. Attaoua C, Vincent LA, Abdel Jaoued A, et al. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids. Fundam Clin Pharmacol 2015; 29:62–71.
81. Shiau RJ, Wu JY, Chiou SJ, et al. Effects of curcumin on nitrosyl-iron complex-mediated DNA cleavage and cytotoxicity. Planta Med 2012; 78:1342–50.
82. Chakraborty G, Kumar S, Mishra R, et al. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PloS One 2012; 7:e33633
83. Abusnina A, Keravis T, Yougbare I, et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 2011; 55:1677–89.
84. Park SY, Jin ML, Kim YH, et al. Aromatic-turmerone inhibits alpha-MSH and IBMX-induced melanogenesis by inactivating CREB and MITF signaling pathways. Arch Dermatol Res 2011; 303:737–44.
85. Prakash M, Kale S, Ghosh I, et al. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin alpha(v)beta(3) interaction. Cell Signal 2011; 23:1563–77.
86. Tu CX, Lin M, Lu SS, et al. Curcumin inhibits melanogenesis in human melanocytes. Phytother Res 2012; 26:174–9.
87. Chatterjee SJ, Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol Ther 2011; 11:216–28.
88. Chen LX, He YJ, Zhao SZ, et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011; 11:229–35.
89. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010; 18:1606–14.
90. Lee JH, Jang JY, Park C, et al. Curcumin suppresses alpha-melanocyte stimulating hormone-stimulated melanogenesis in B16F10 cells. Int J Mol Med 2010; 26:101–6.
91. Wang L, Shen Y, Song R, et al. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 2009; 76:1238–45.
92. Bill MA, Bakan C, Benson DM, Jr, et al. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009; 8:2726–35.
93. Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. Brain Res 2009; 1266:130–8.
94. Gui F, Ma WF, Cai SH, et al. Preliminary study on molecular mechanism of curcumine anti-mouse melanoma. Zhongyaocai 2008; 31:1685–9.
95. Bakhshi J, Weinstein L, Poksay KS, et al. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis 2008; 13:904–14.
96. Marin YE, Wall BA, Wang S, et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007; 17:274–83.
97. Qiu S, Tan SS, Zhang JA, et al. Apoptosis induced by curcumin and its effect on c-myc and caspase-3 expressions in human melanoma A375 cell line. Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA 2005; 25:1517–21.
98. Depeille P, Cuq P, Passagne I, et al. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 2005; 93:216–23.
99. Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 2004; 111:381–7.
100. Banerji A, Chakrabarti J, Mitra A, et al. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004; 211:235–42.
101. Zheng M, Ekmekcioglu S, Walch ET, et al. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004; 14:165–71.
102. Depeille P, Cuq P, Mary S, et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004; 65:897–905.
103. Ray S, Chattopadhyay N, Mitra A, et al. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol 2003; 22:49–58.
104. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 2000; 7:303–8.
105. Iersel ML, Ploemen JP, Struik I, et al. Inhibition of glutathione S-transferase activity in human melanoma cells by alpha, beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact 1996; 102:117–32.
106. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995; 95:221–5.
107. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41:1955–68.
108. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005; 1056:206–17.
109. Chen JW, Tang YL, Liu H, et al. Anti-proliferative and anti-metastatic effects of curcumin on oral cancer cells. WCJS 2011; 29:83–6
110. Waghela BN, Sharma A, Dhumale S, et al. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells. PloS One 2015; 10:e0117526
111. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 2008; 76:1590–611.
112. Lo CY, Liu PL, Lin LC, et al. Antimelanoma and antityrosinase from Alpinia galangal constituents. Scientific World J 2013; 2013:186505
113. Faiao-Flores F, Suarez JA, Maria-Engler SS, et al. The curcumin analog DM-1 induces apoptotic cell death in melanoma. Tumour 2013; 34:1119–29.
114. Pisano M, Pagnan G, Dettori MA, et al. Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol Cancer 2010; 9:137
115. Dahmke IN, Boettcher SP, Groh M, et al. Cooking enhances curcumin anti-cancerogenic activity through pyrolytic formation of “deketene curcumin”. Food Chem 2014; 151:514–9.
116. Leyon PV, Kuttan G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumour specific angiogenesis. J Exp Clin Cancer Res 2003; 22:77–83.
117. Arezki A, Chabot G, Quentin L, et al. Synthesis and biological evaluation of novel ferrocenyl curcuminoid derivatives. Med Chem Commun 2011; 2:190–5.
118. Hosoya T, Nakata A, Yamasaki F, et al. Curcumin-like diarylpentanoid analogues as melanogenesis inhibitors. J Nat Med 2012; 66:166–76.
119. Lamoral-Theys D, Wauthoz N, Heffeter P, et al. Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med 2012; 16:1421–34.
120. Ruan BF, Lu X, Li TT, et al. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents. Bioorg Med Chem 2012; 20:1113–21.
121. Faiao-Flores F, Suarez JA, Soto-Cerrato V, et al. Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. Tumour Biol 2013; 34:1235–43.
122. Bill MA, Fuchs JR, Li C, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010; 9:165
123. Bill MA, Nicholas C, Mace TA, et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PloS One 2012; 7:e40724
124. Rozzo C, Fanciulli M, Fraumene C, et al. Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Mol Cancer 2013; 12:37
125. Valiahdi SM, Iranshahi M, Sahebkar A. Cytotoxic activities of phytochemicals from Ferula species. DARU 2013; 21:39
126. Dettori MA, Fabbri D, Pisano M, et al. 4-substituted-2-methoxyphenol: suitable building block to prepare new bioactive natural-like hydroxylated biphenyls. Lett Drug Des Discov 2015; 12:131–9.
127. Poorghorban M, Das U, Alaidi O, et al. Characterization of the host-guest complex of a curcumin analog with beta-cyclodextrin and beta-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. Int J Nanomedicine 2015; 10:503–15.
128. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009; 14:226–46.
129. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceCancer. Res Treat 2014; 46:2–18.
130. Kurien BT, Harris VM, Quadri SM, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. Lupus Sci Med 2015; 2:e000114
131. Kurien BT, Scofield RH. Oral administration of heat-solubilized curcumin for potentially increasing curcumin bioavailability in experimental animals. Int J Cancer 2009; 125:1992–3.
132. Kurien BT, Scofield RH. Heat-solubilized curcumin should be considered in clinical trials for increasing bioavailability. Clin Cancer Res 2009; 15:747
133. Alam S, Panda JJ, Chauhan VS. Novel dipeptide nanoparticles for effective curcumin delivery. Int J Nanomedicine 2012; 7:4207–22.
134. Karewicz A, Bielska D, Loboda A, et al. Curcumin-containing liposomes stabilized by thin layers of chitosan derivatives. Colloids Surf B Biointerfaces 2013; 109:307–16.
135. Cui M, Naczynski DJ, Zevon M, et al. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv Healthc Mater 2013; 2:1236–45.
136. Zhao Y, Lin D, Wu F, et al. Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery. Int J Mol Sci 2014; 15:17565–76.
137. Chen Y, Wu Q, Zhang Z, et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules 2012; 17:5972–87.
138. Wadajkar AS, Bhavsar Z, Ko CY, et al. Multifunctional particles for melanoma-targeted drug delivery. Acta Biomater 2012; 8:2996–3004.
139. Michel D, Chitanda JM, Balogh R, et al. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur J Pharm Biopharm 2012; 81:548–56.
140. de Souza FF, dos Santos MC, dos Passos DC, et al. Curcumin associated magnetite nanoparticles inhibit in vitro melanoma cell growth. J Nanosci Nanotechnol 2011; 11:7603–10.
141. Mangalathillam S, Rejinold NS, Nair A, et al. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale 2012; 4:239–50.
142. Sun Y, Du L, Liu Y, et al. Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-beta-cyclodextrin for melanoma treatment. Int J Pharm 2014; 469:31–9.
143. Ma Z, Haddadi A, Molavi O, et al. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008; 86:300–10.
144. Langone P, Debata PR, Dolai S, et al. Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int J Cancer 2012; 131:E569–78.
145. Yu T, Li J, Qiu Y, et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation. Mol Cell Biochem 2012; 361:47–54.
146. Mazzarino L, Silva LF, Curta JC, et al. Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: an in vitro and in vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study. J Biomed Nanotechnol 2011; 7:406–14.
147. Sun A, Shoji M, Lu YJ, et al. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 2006; 49:3153–8.
148. Mazzarino L, Otsuka I, Halila S, et al. Xyloglucan-block-poly(-caprolactone) copolymer nanoparticles coated with chitosan as biocompatible mucoadhesive drug delivery system. Macromol Biosci 2014; 14:709–19.
149. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215–33.
150. Mirzaei H, Gholamin S, Shahidsales S, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016; 53:25–32.
151. Schickel R, Boyerinas B, Park SM, et al. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27:5959–74.
152. Salarini R, Sahebkar A, Mirzaei H, et al. Epi-drugs and epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets 2015.
153. Gholamin S, Pasdar A, Khorrami M, et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. Curr Pharm Des 2016; 22:397–403.
154. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136:586–91.
155. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharmaceut Res 2010; 27:1014–26.
156. Zhang P, Bai H, Liu G, et al. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. Toxicol Lett 2015; 234:151–61.
157. Toden S, Okugawa Y, Buhrmann C, et al. Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev Res (Phila) 2015; 8:431–43.
158. Sadeghipour A, Eidi M, Ilchizadeh Kavgani A, et al. Lipid lowering effect of punica granatum L. Peel in high lipid diet fed male rats. Evid Based Complement Alternat Med 2014; 2014:432650
159. Ali S, Ahmad A, Aboukameel A, et al. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett 2012; 31917381.
160. Ye M, Zhang J, Zhang J, et al. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett 2015; 357:196–205.
161. Zhang J, Du Y, Wu C, et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 2010; 24:1217–23.
162. Gao W, Chan JY, Wong TS. Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p. Clin Sci 2014; 127:571–9.
163. Zhao SF, Zhang X, Zhang XJ, et al. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. APJCP 2014; 15:3363–8.
164. Yallapu MM, Khan S, Maher DM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 2014; 35:8635–48.
165. Li X, Xie W, Xie C, et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferationPhytother. RES 2014; 28:1553–60.
166. Liang HH, Wei PL, Hung CS, et al. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol 2013; 34:3209–18.
167. Gao SM, Yang JJ, Chen CQ, et al. Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. JECCR 2012; 31:27
168. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14:4491–9.
169. Mahammedi H, Planchat E, Pouget M, et al. The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study. Oncology 2016; 90:69–78.
170. Hejazi J, Rastmanesh R, Taleban FA, et al. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: a double blinded, randomized, placebo-controlled study. Nutr Cancer 2016; 68:77–85.